Mipomersen, an oligonucleotide to apolipoprotein B-100
, reduces lipoprotein(a) in various populations with hypercholesterolemia: Results of 4 phase 3 trials.
Structure of apolipoprotein B-100
in low density lipoproteins.
This protein is apolipoprotein B-100
(apoB-100) and was completely sequenced for the first time in 1986 by several labs thanks to genetic investigations [22-25].
We investigated the potential role and mechanism of action of an indole-based compound, indole-3-carbinol (I3C), on apolipoprotein B-100
(apoB) production using HepG2 cells.
In human plasma apolipoprotein B occurs in two forms apolipoprotein B-100
and apolipoprotein B-48, which are derived from a single gene [39-43] on the short arm of chromosome 2.
Upon conversion, cholesterol and apolipoprotein B-100
become the predominant components of LDLs and apolipoprotein B-100
is the biological marker that allows LDLs to bind to cellular receptors.
Lipoprotein(a) [Lp(a)], first described by Berg in 1963, is a plasma lipoprotein consisting of a cholesterol-rich LDL particle with one molecule of apolipoprotein B-100
and a molecule of apolipoprotein A .
Mipomersen, formerly ISIS 301012, is a lipid-lowering drug targeting apolipoprotein B-100
. Currently in phase 3 development, mipomersen has been shown in phase 2 trials to reduce cholesterol and other atherogenic lipids more than 40 percent beyond reductions achieved with current standard lipid-lowering drugs, enabling more patients to achieve lipid targets.
In a cross-sectional analysis of apparently healthy women aged 45 years and older who were followed for 10 years, the women with any history of migraine had small but statistically significant increased total cholesterol, non-HDL cholesterol, apolipoprotein B-100
, and C-reactive protein (CRP) levels, compared with women who had no history of migraine, reported Dr.
The analysis also showed that the ratio of total cholesterol to HDL cholesterol was at least as good for predicting the risk of the ocurrence of cardiovascular events as was the ratio of apolipoprotein B-100
to HDL lipoprotein cholesterol (JAMA 2005;294:326-33).
From this triglyceride, the liver makes VLDL, consisting of a rich triglyceride core and an outer surface made of free cholesterol, phospholipids, apolipoprotein B-100
(apoB-100), and apo-E (Guyton & Hall, 2000; Tulenko & Sumner, 2002).
There were no significant changes in serum total cholesterol, triglyceride, LDL-cholesterol, HDL-cholesterol or apolipoprotein B-100
concentrations with black tea ingestion.